Sheffer v. Novartis Pharmaceuticals Corporation

873 F. Supp. 2d 371, 2012 U.S. Dist. LEXIS 94734
CourtDistrict Court, District of Columbia
DecidedJuly 10, 2012
DocketCivil Action No. 2008-0904
StatusPublished
Cited by43 cases

This text of 873 F. Supp. 2d 371 (Sheffer v. Novartis Pharmaceuticals Corporation) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sheffer v. Novartis Pharmaceuticals Corporation, 873 F. Supp. 2d 371, 2012 U.S. Dist. LEXIS 94734 (D.D.C. 2012).

Opinion

MEMORANDUM OPINION

JOHN D. BATES, District Judge.

Plaintiffs Shirley and Scott Sheffer bring this action against defendant Novartis Pharmaceuticals Corporation, alleging that Ms. Sheffer suffered injuries as a result of her treatment with drugs market *374 ed and distributed by Novartis. Defendant now moves to transfer venue, arguing that the Southern District of Ohio is a more convenient and just forum for this litigation. For the reasons stated below, the Court finds that private and public interest considerations outweigh the deference given to plaintiffs’ choice of forum. Accordingly, the Court will grant defendant’s motion and transfer this action to the Southern District of Ohio.

I. Background

The Sheffers are residents of Yorkshire, Ohio, located in the Southern District of Ohio. Compl. ¶ 2. All of the events leading up to this lawsuit occurred in Yorkshire and the surrounding area. Id.) Def.’s Mot. to Change Venue at 1 (May 7, 2012) [Docket Entry 9]. Novartis is a multinational corporation that markets and distributes Aredia, a drug used to treat diseases that have metastasized to bone, throughout all fifty states and the District of Columbia. Compl. ¶¶ 5, 7.

Ms. Sheffer’s physicians treated her for breast cancer by infusing her with Aredia. Id. ¶ 2. Plaintiffs claim that Aredia caused the bone tissue of Ms. Sheffer’s jaw to die, a painful and disfiguring condition known as osteonecrosis. Id. ¶ 1. They further claim that defendant knew or should have known of this adverse effect, and nonetheless continued to market and distribute Aredia. Id. ¶¶ 12-16.

Invoking diversity jurisdiction, plaintiffs filed suit in this district on May 27, 2008. Id. ¶ 6. They seek compensatory and punitive damages under a number of different theories, including strict liability, failure to warn, and, in Mr. Sheffer’s case, loss of consortium. Id. ¶¶ 22-54. On August 1, 2008, the Judicial Panel on Multidistrict Litigation transferred this case to the Middle District of Tennessee, where hundreds of similar lawsuits have been consolidated to litigate common factual questions more efficiently. See In re Aredia and Zometa Prods. Liab. Litig., No. 3:06-md-1760 (M.D.Tenn.) (“MDL-1760”); Letter from J.P.M.L. (Aug. 1, 2008) [Docket Entry 2], The Panel having remanded the case back to this Court, defendant now moves to transfer venue. See Defs Mot.; Conditional Remand Order (Jan. 9, 2012) [Docket Entry 4].

II. Discussion

Novartis seeks to transfer this case to the Southern District of Ohio under 28 U.S.C. § 1404(a), which provides:

For the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought.

Section 1404(a) is a “federal judicial housekeeping measure” that allows a district court to “authorize a change of courtrooms” based on an “individualized, case-by-case consideration of convenience and fairness.” Van Dusen v. Barrack, 376 U.S. 612, 622, 636-37, 84 S.Ct. 805, 11 L.Ed.2d 945 (1964). The burden is on the moving party to establish that transfer is proper. Trout Unlimited v. U.S. Dep’t of Agric., 944 F.Supp. 13, 16 (D.D.C.1996).

The threshold requirement of § 1404(a) is met here: the transferee forum is a district “where [the action] might have been brought.” See id. Venue and jurisdiction are proper in both the Southern District of Ohio and the District of the District of Columbia. 1 Neither party dis *375 putes that the action could have been brought in either district. See Def.’s Mot.; Pls.’ Mem. in Opp’n to Def's Mot. (May 18, 2012) [Docket Entry 10].

In deciding whether the “convenience of parties and witnesses” and “the interest of justice” warrant transfer, courts have identified several relevant factors. Mirroring the statutory language, these factors fall under two broad headings, private-interest factors and public-interest factors. See Trout Unlimited, 944 F.Supp. at 16. “If the balance of private and public interests favors a transfer of venue, then a court may order a transfer.” Montgomery v. STG Int’l, Inc., 532 F.Supp.2d 29, 32 (D.D.C.2008).

A. Private-interest Factors

In determining whether “the convenience of parties and witnesses” favors transfer, courts consider the following private-interest factors:

(1) the plaintiffs choice of forum;
(2) the defendant’s choice of forum;
(3) whether the claim arose elsewhere;
(4) the convenience of the parties;
(5) the convenience of the witnesses, particularly if important witnesses may actually be unavailable to give live trial testimony in one of the districts; and
(6) the ease of access to sources of proof.

Id. at 32-33; see Trout Unlimited, 944 F.Supp. at 16. The occasional redundancy of these factors serves a noble goal: ensuring that each motion to transfer gets thorough consideration. The Court will consider each factor in turn. On the whole, all of the private-interest factors are either neutral or favor transfer, with the exception of the plaintiffs choice of forum, which weighs against transfer.

1. Plaintiff’s Choice of Forum

The plaintiffs choice of forum is a “paramount consideration in any determination of a transfer request.” Thayer/Patricof Educ. Funding, LLC v. Pryor Res., 196 F.Supp.2d 21, 31 (D.D.C.2002) (internal quotation marks omitted). The plaintiffs considerable freedom to bring a lawsuit in an advantageous forum should not be compromised by a transfer that “merely shift[s] the inconvenience ... from one party to the other.” 15 Charles Alan Wright & Arthur R. Miller, Federal Practice and Procedure § 3848 (3d ed.1998) (citing Van Dusen, 376 U.S. at 646, 84 S.Ct. 805). The “substantial deference” 2 *376 given to the plaintiffs choice of forum makes this different from other cases where plaintiffs have moved to transfer. Greater Yellowstone Coal. v. Bosworth, 180 F.Supp.2d 124, 128 (D.D.C.2001). In support of its motion to transfer, Novartis attached several motions and orders requesting and granting transfers from lawsuits involving similar claims. Def.’s Reply to Opp’n to Mot. to Change Venue (May 22, 2012) [Docket Entry 11] Exs. 1-6.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
873 F. Supp. 2d 371, 2012 U.S. Dist. LEXIS 94734, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sheffer-v-novartis-pharmaceuticals-corporation-dcd-2012.